Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Reply to ‘Absence of JAK-2 (Val617Phe) point mutations in multiple myeloma’ by Dr Qin Huang et al. referred to ‘Screening of JAK2 V617F mutation in multiple myeloma’ from Fiorini A et al. published in Leukemia 2006, October 20

Leukemia volume 21, pages 814–815 (2007)Cite this article

Cytokines of interleukin-6 family are major survival and growth factors in vivo and in vitro for multiple myeloma cells (MM). It induces intracellular signaling through STAT family proteins that are activated by JAK family protein tyrosine kinases.1, 2, 3

When methods became available, we investigated the presence of JAK2 V617F mutation in MM to see if this alteration could contribute to the pathogenesis of this hematological disorder. We analysed 93 patients affected by MM mostly taken at diagnosis for the presence of JAK2 V617F mutation and we did not find any positive case.4

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 2000; 109: 823–828.

    Article  CAS  Google Scholar 

  2. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki Z, Savino R et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105–115.

    Article  CAS  Google Scholar 

  3. Abroun S, Ishikawa H, Tsuyama N, Liu S, Otsuyama Km Zheng X, Obata M et al. Receptor sinergy of interleukin-6 (IL-6) and insulin-like growth factor-1 in myeloma cells that highly express IL-6 receptor alpha. Blood 2004; 103: 2291–2298.

    Article  CAS  Google Scholar 

  4. Fiorini A, Farina G, Reddiconto G, Palladino M, Rossi E, Za T et al. Screening of JAK2 V617F mutation in multiple myeloma. Leukemia 2006; 20: 1912–1913.

    Article  CAS  Google Scholar 

  5. Bergsagel PL, Masellis S, Szczepek A, Mant MJ, Belch AR, Pilarski LM . In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56 and monotypic immunoglobulin light chain. Blood 1995; 85: 436.

    CAS  Google Scholar 

  6. Baxter EJ, Scott LM, Campbell PJ, East C, Fourclas N, Swanton S et al. Cancer genome project. Acquired mutation of the tyrosine kinase JAK 2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

    Article  CAS  Google Scholar 

  7. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

    Article  CAS  Google Scholar 

  8. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2 activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukaemia, but not in acute lymphoblastic leukaemia or chronic lymphocytic leukaemia. Blood 2005; 106: 3377–3379.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Catholic University, L.go A.Gemelli 8, Rome, Italy,

    A Fiorini, G Farina, G Reddiconto, M Palladino, E Rossi, T Za, L Laurenti, S Giammarco, P Chiusolo, G Leone & S Sica

Authors
  1. A Fiorini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Farina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Reddiconto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Palladino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Za
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Laurenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Giammarco
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P Chiusolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Leone
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Sica
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Fiorini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fiorini, A., Farina, G., Reddiconto, G. et al. Reply to ‘Absence of JAK-2 (Val617Phe) point mutations in multiple myeloma’ by Dr Qin Huang et al. referred to ‘Screening of JAK2 V617F mutation in multiple myeloma’ from Fiorini A et al. published in Leukemia 2006, October 20. Leukemia 21, 814–815 (2007). https://doi.org/10.1038/sj.leu.2404553

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404553

Search

Advanced search

Quick links